Summary:
- This article reports the results of a randomized controlled trial evaluating the efficacy of a new COVID-19 vaccine candidate, NVX-CoV2373, developed by Novavax.
- The study found that the vaccine demonstrated an overall efficacy of 90.4% in preventing mild, moderate, or severe COVID-19 illness, with no severe cases reported in the vaccine group.
- The vaccine was well-tolerated, with a safety profile similar to placebo, and the findings support the further development and potential authorization of this COVID-19 vaccine candidate.